- Clinical Trials
- April 2024
- 60 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- April 2024
Global
From €400EUR$440USD£355GBP
- Report
- March 2018
- 330 Pages
Global
From €2919EUR$3,000USD£2,501GBP
- Clinical Trials
- February 2018
- 225 Pages
Global
From €2335EUR$2,400USD£2,000GBP
- Report
- January 2021
- 600 Pages
United States
From €2724EUR$2,800USD£2,334GBP
- Report
- November 2020
- 124 Pages
Global
From €934EUR$960USD£800GBP
€1168EUR$1,200USD£1,000GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9730EUR$10,000USD£8,335GBP
- Report
- January 2021
- 124 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Report
- April 2023
- 129 Pages
Global
€4865EUR$5,000USD£4,168GBP
- Report
- March 2024
- 115 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- July 2023
- 97 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- August 2022
- 74 Pages
Global
From €1946EUR$2,000USD£1,667GBP
Cabazitaxel is an oncology drug used to treat metastatic castration-resistant prostate cancer (mCRPC). It is a semi-synthetic taxane, derived from the bark of the Pacific yew tree, and is administered intravenously. It works by inhibiting the growth of cancer cells by disrupting the microtubules that are essential for cell division. Cabazitaxel is used in combination with prednisone or prednisolone, and is typically prescribed after other treatments have failed.
Cabazitaxel is approved for use in the United States, Europe, and other countries. It is marketed by Sanofi under the brand name Jevtana, and is available in vials containing 20 mg/ml of cabazitaxel.
The cabazitaxel market is highly competitive, with several companies offering generic versions of the drug. Companies in the market include Sanofi, Mylan, Teva Pharmaceuticals, Accord Healthcare, and Sun Pharmaceuticals. Show Less Read more
